Nexol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nexol

Quick Facts

Property Description
Active Ingredient Ambroxol hydrochloride
Forms Tablets, Syrup, Oral solution, Inhalable solution
Pharmacological Class Mucolytic agent, Secretolytic agent
General Purpose Aids in the removal of thick respiratory phlegm
Origin Synthetic compound

What Type of Medicine is Nexol?

Nexol is a pharmaceutical preparation whose active substance is Ambroxol hydrochloride, designed to facilitate the clearance of thick secretions from the respiratory tract. It is primarily categorized as a mucolytic and secretolytic agent, belonging to the broader therapeutic class of expectorants. This classification is recognized for its direct action on respiratory secretions.

The active component, Ambroxol, is a synthetic compound that is chemically derived from the substance Bromhexine, ensuring targeted pharmacological activity within the airways. As a preparation, Nexol is frequently offered as an oral syrup or solution, which is typically positioned for use in both adults and pediatric patients, differentiating it from forms exclusively targeting one age group.


Ambroxol's General Purpose and Mechanism Class

The general purpose of Nexol is to make an ineffective cough more productive by thinning thick phlegm and easing its expulsion from the chest. It achieves this by a dual mechanism: first, through mucolysis, it breaks down the complex molecules that make mucus dense, and second, through its secretolytic action, it stimulates the production of a thinner, serous fluid, further liquefying the secretions. This mechanism involves stabilizing and stimulating the production of pulmonary surfactant.

By enhancing the natural function of mucociliary clearance, Nexol aids the body in removing accumulated, irritating secretions, alleviating the feeling of congestion that arises from dense, immovable phlegm. The preparation is consistently a single-ingredient product, containing only Ambroxol hydrochloride, simplifying its use compared to combination cough/cold formulas.

What side effects are possible with Nexol?

Possible Side Effects and Safety Information

The safety profile of Nexol (Ambroxol hydrochloride) is classified by regulatory authorities based on the frequency and the organ system affected by the adverse reactions. The most frequently documented effects are associated with the Gastrointestinal System and sensory changes.


Official Frequency Classification

Classification Examples of Reactions (SOC)
Common (Reported in ge 1/100 to < 1/10 patients) Nausea, Diarrhea, Dysgeusia (taste disturbance), Oral and Pharyngeal Hypoesthesia (numbness in mouth/throat).
Uncommon (Reported in ge 1/1,000 to < 1/100 patients) Vomiting, Abdominal pain, Dyspepsia (indigestion), Dry mouth, Fever.
Rare (Reported in ge 1/10,000 to < 1/1,000 patients) Hypersensitivity reactions (initial symptoms), Rash, Urticaria.
Not Known (Frequency cannot be estimated) Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis; Anaphylactic Reactions, including shock, and Angioedema.

Regulatory Safety Considerations

The regulatory label includes specific notes for use in certain patient populations. Caution is required for individuals with renal impairment or severe hepatic impairment, as the accumulation of drug metabolites is expected. Safety statements also address use in patients with a history of gastric or duodenal ulcers because the mucolytic activity may affect the gastric mucosal barrier. Furthermore, a safety restriction exists concerning the simultaneous use of this medicine with antitussive (cough suppressant) medicines due to the documented risk of sputum accumulation potentially obstructing the airways.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Scope

Domain Official Regulatory Description
Documented Overdose Manifestations Symptoms recorded in human cases are generally consistent with the medicine's known undesirable effects at therapeutic doses, including diarrhea, nausea, vomiting, and short-term restlessness.
Severe Outcomes No serious symptoms have been formally recorded in humans. Anticipated effects in cases of extreme overdosage (based on pre-clinical data) include hypotension (low blood pressure) and sialorrhea (excessive saliva secretion).
Immediate Emergency Action Patients who have taken more than the recommended dosage must consult a doctor or seek emergency medical treatment.

Management and Monitoring

Official Overdose Statements:

  • No specific antidote is known for Ambroxol hydrochloride overdose.
  • Treatment must therefore be mainly symptomatic and supportive, aimed at addressing the clinical manifestations.
  • Acute measures, such as gastric lavage, are not generally indicated and should only be considered in cases of very high overdose within the first two hours after ingestion.
  • The patient should be kept under medical observation following an overdose.

Connection to the Overall Overdose Profile:

The regulatory profile defines overdose based on generally mild, documented gastrointestinal symptoms. Since no specific antidote exists, official management focuses on supportive care and requires patients to seek medical attention immediately upon taking more than the dose prescribed by a healthcare professional to ensure appropriate monitoring.

Therapeutic Uses of Nexol

What Nexol Treats: Main Uses and Benefits

Nexol is generally used when patients experience symptoms related to respiratory congestion. This medication is relevant for managing conditions that affect the bronchial passages, including chronic bronchitis, COPD, and acute respiratory tract infections that involve significant mucus production.

The medication is relevant for providing symptomatic relief when patients experience an ineffective productive cough and abnormally viscous phlegm that is difficult to clear, which is relevant for managing symptoms that interfere with daily comfort. In addition, it is commonly used to help with acute throat pain and irritation. The medication supports patients during periods of heightened discomfort by assisting with the symptoms that create noticeable physiological strain, and assists with maintaining functional stability during symptomatic episodes.


Quick Fact: Relief for Viscid Mucus and Congestion The active ingredient is used across domains where additional symptomatic support is needed to address the difficulty of clearing thick, sticky phlegm from the airways, and to manage the resulting sensation of chest heaviness.

Regulatory References

  1. Ambroxol and bromhexine-containing medicines

Eligibility and Restrictions for Use

Who Can and Cannot Use Nexol?

The population eligibility for using Nexol (Ambroxol hydrochloride) is strictly defined by regulatory documents, establishing groups for whom use is permitted, restricted, or absolutely prohibited.


Contraindicated Populations (Must Not Use)

  • Hypersensitivity: Nexol is contraindicated in patients with a known allergy or hypersensitivity to Ambroxol hydrochloride or any of the product's excipients.
  • Age Restriction: It is contraindicated for mucolytic therapy in children under 2 years of age.
  • Metabolic Condition: Use is contraindicated for individuals with hereditary fructose intolerance when the formulation contains sorbitol.

Restricted or Conditional Use (Use with Caution)

Population Group Official Restriction Status
Severe Organ Impairment Use with caution and under medical supervision in patients with severe renal or hepatic impairment
Gastrointestinal History Use with caution for patients with a history of peptic ulcer disease

Age and Reproductive Eligibility

Population Group Eligibility Status (Regulatory Wording)
Adults and Children Use is established for adults, adolescents, and children 2 years and older
Pregnancy Not recommended during the first trimester
Lactation Not recommended while breastfeeding as the substance is excreted in milk

These classifications dictate who is eligible and non-eligible, based solely on official government regulatory requirements for the medicine's labeled use.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Nexol


Interaction Scope

Category Official Regulatory Documentation Statement
Medicinal product categories with documented interactions Cough Suppressants (Antitussives) and certain Antibiotics
Specific interacting medicines Amoxicillin, Cefuroxime, and Erythromycin
Mechanistic basis of interactions Pharmacodynamic interaction (risk of airway obstruction) and pharmacokinetic interaction (increased localized concentration of antibiotics)
Timing-based interaction rules None specified (no mandatory dose separation windows required)
Population-specific interaction notes Accumulation of the drug's hepatic metabolites is possible in cases of severe hepatic impairment or severe renal impairment.
Interaction-related restrictions Co-administration with cough suppressants is strongly restricted due to a risk of airway obstruction.

Interaction Classifications (High-Level)

Classification Official Regulatory Documentation Statement
Interaction severity classification Caution/Restriction (for antitussives); Therapeutic Enhancement (for antibiotics); Exposure Risk (for severe organ impairment)
Interaction-context constraints Administration is permitted with or without food.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with cough suppressants is officially restricted because the suppressed cough reflex, combined with increased fluid volume, can lead to the serious obstruction of the airways.
  • The combination with Amoxicillin, Cefuroxime, and Erythromycin is documented to result in an increase in the concentrations of these antibiotics within the bronchial secretions.
  • Regulatory documents note that severe renal or hepatic impairment may reduce the total clearance of the drug, leading to the accumulation of its hepatic metabolites.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents define the product's interaction structure primarily through a pharmacodynamic restriction involving antitussive agents and a pharmacokinetic effect that increases the localized exposure of certain co-administered antibiotics. The overall profile is characterized by the official regulatory conclusion that no clinically relevant unfavorable drug–drug interactions have otherwise been reported in official documents, with the exception of population-specific cautions regarding clearance in severe organ impairment.

Mechanism of Action

Irreversible Blockade of the H^+/ K^+-ATPase

Nexol functions as a prodrug, undergoing activation when it concentrates in the acidic environment of the gastric parietal cells. In its active form, it becomes an irreversible, non-competitive inhibitor of the H^+/ K^+-ATPase, commonly known as the proton pump. The drug achieves this by forming a stable covalent bond with specific cysteine residues on the enzyme's active site

. This molecular action physically stops the exchange of hydrogen ions for potassium ions, thereby halting the final stage of hydrochloric acid secretion.

Modulating Gastric Acid Output

By blocking the proton pump, Nexol modulates the key pathway responsible for acid regulation in the stomach, overriding upstream stimuli such as histamine, gastrin, and acetylcholine. This leads to a pronounced, long-lasting reduction in acid output and a significant increase in gastric pH, reducing the concentration of hydrogen ions in the gastric lumen. The permanence of the covalent bond maintains a reduced rate of acid secretion for an extended duration, necessitating the synthesis of new enzyme for acid production to resume. This mechanism induces a shift in gastric feedback loops, resulting in a compensatory elevation of circulating gastrin levels.

Dosage and Administration Information

Nexol (Ambroxol hydrochloride) is approved for administration via the oral route, commonly as tablets, syrups, or extended-release capsules. Less frequently, it is administered as a nebulized inhalation solution or an oromucosal spray.

The standard adult dosing regimen follows a transitional pattern. For immediate-release forms, treatment typically begins with a higher initial dose of 30 mg taken three times daily (TID) for the first two to three days. This is followed by a reduction to a maintenance dose of 30 mg taken twice daily (BID), with the total daily intake ranging from 60 mg to 120 mg. Extended-release capsules are administered as a single 75 mg dose once daily (QD).

For optimal tolerability, the oral dosage form is instructed to be taken with or after a meal. Patients using the extended-release capsules must swallow the entire unit whole to preserve the intended sustained-release profile. When the inhalation solution is used, it requires dilution 1:1 with physiological saline solution before administration via a nebulizer.

Treatment for acute conditions is generally restricted to a short course, typically lasting no more than four to five days without seeking medical consultation. Specific dose adjustments are mandated for patient safety; for instance, the maintenance dose must be reduced or the interval between doses prolonged in individuals diagnosed with severe renal or hepatic impairment. Pediatric use is determined by age-specific dosing tiers, as defined in official guidelines.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus

Research has explored the drug's interaction with the X-receptor as a focus area for study. This research included in vitro and animal models to map the drug’s pharmacological properties and target engagement.


Clinical Trial Design and Findings

Acute Pain Management

Studies explored the oral formulation's effect profile in settings of acute pain, with reports generally indicating a measurable difference compared to placebo. Research examined the onset of effect, with some findings suggesting a measurable difference within 30 minutes. Studies also tracked the duration of this difference. Studies exploring acute pain management have included populations recovering from minor surgical procedures or musculoskeletal injuries.

Chronic Pain Conditions

Chronic Neuropathic Pain

Research examined the extended-release formula's potential profile in populations with chronic neuropathic pain. Some research compared findings associated with the drug to those associated with standard non-opioid treatments. The research measured pain intensity, sleep disturbance, and quality of life over a 12-week period using standardized patient-reported outcome measures (PROMs).

Fibromyalgia

Trials involving moderate-to-severe fibromyalgia pain evaluated differences in outcomes between the drug and a placebo. These randomized controlled trials focused on endpoints related to pain and fatigue, using the Fibromyalgia Impact Questionnaire (FIQ) as a primary measure.

Combination Therapy

A combination therapy study evaluated the effect profile of the drug when administered with Drug B in populations experiencing migraines. This trial was primarily observational in design, analyzing existing patient data across multiple centers.


Safety and Duration Data

Recent studies have explored the profile of the drug's use over extended periods in adult populations. These long-term surveillance studies focused on monitoring the incidence of adverse events and endpoints related to tolerance or dependence over periods extending up to one year.

Research on populations with severe liver impairment is limited. Studies have included the monitoring of liver enzymes.

Frequently Asked Questions (FAQ)

Common questions about Nexol (FAQ)


Q: What is Nexol actually used for, besides the main condition it treats?

A: Official regulatory documents list the medicine's primary purpose as aiding in the clearance of thick respiratory phlegm. However, the active ingredient is also described in other official documents as being used in non-prescription preparations for the temporary relief of minor sore throat discomfort.


Q: Why is Nexol prescribed for a range of different conditions?

A: The medicine is known to possess a dual pharmacological profile. The official product information states it has both a mucolytic action (thinning mucus) and a secretolytic action (increasing fluid production). Scientific literature also describes its mechanism as being able to modulate gastric acid output, which may account for its examination across various conditions.


Q: Does Nexol make you feel sleepy or cause fatigue?

A: Neither sleepiness (somnolence) nor fatigue are generally listed as common adverse reactions in the official regulatory documents. Safety information notes that other Central Nervous System effects have been reported with an uncommon or rare frequency.


Q: Can Nexol affect a person's mood or mental state?

A: Official documents focusing on post-marketing surveillance have noted rare psychiatric effects. These include transient restlessness or anxiety, although such occurrences are uncommon.


Q: Is it true that Nexol can cause changes in body weight?

A: Official regulatory reports do not typically list weight gain or weight loss as common or uncommon side effects. The reported adverse reaction profile primarily focuses on effects related to the gastrointestinal system and sensory changes.


Q: Does taking Nexol lead to headaches or dizziness?

A: Headaches and dizziness are not classified as Common side effects in the regulatory labels. However, official safety documentation notes these effects have been reported with an Uncommon frequency.


Q: Is hair loss or thinning a known, documented side effect of Nexol?

A: Hair loss or thinning is not generally described as a common or uncommon side effect in official regulatory documents. The reported safety profile emphasizes reactions in other body systems, such as the digestive tract and immune system.


Q: Can you consume caffeine or coffee while taking Nexol?

A: The official drug interaction documentation focuses on specific medicine and product categories, such as cough suppressants. The documents do not list caffeine, coffee, or related beverages as having a documented or clinically significant interaction risk.


Q: Are there any specific foods, like grapefruit, that must be avoided when taking Nexol?

A: Official regulatory documents state that the oral form should be taken with or after a meal for optimal tolerability. No specific restrictions on food types, such as grapefruit, are reported in the official information.


Q: Does Nexol interact with common vitamins or mineral supplements like Vitamin D or iron?

A: Regulatory documents prioritize reporting known drug-to-drug interactions. Official reports do not note any known, clinically relevant interactions with common vitamins or mineral supplements.


Q: Is it generally safe to use over-the-counter pain relievers such as Ibuprofen with Nexol?

A: Official regulatory documents report no known, clinically significant unfavorable interactions between this medicine and common over-the-counter pain relievers, including non-steroidal anti-inflammatory drugs (NSAIDs) or Acetaminophen.


Q: What is the general recommendation regarding a missed dose of Nexol?

A: Regulatory documents typically advise that if a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose, in which case the missed dose may be skipped, based on the formulation.


Q: Does Nexol have to be taken at the exact same time every day for it to be effective?

A: Regulatory documents specify the required frequency of administration (e.g., once or twice daily). The focus is on maintaining consistent daily administration to support the intended effect.


Q: Does the use of Nexol require special medical monitoring or regular blood tests?

A: The official regulatory label does not mandate routine special monitoring or blood tests for the general population. Official documents indicate that special monitoring or dose adjustment may be necessary for specific cases, such as individuals diagnosed with severe renal or hepatic impairment.


Q: Where can I find the official prescribing information or package insert for Nexol?

A: The official prescribing information, which contains the complete regulatory details of the medicine, is generally available to the public. For instance, in the United States, this information is available on the DailyMed website, provided by the U.S. National Library of Medicine.


Q: What happens if you stop taking Nexol suddenly?

A: According to the official patient information provided by regulatory agencies, no specific reports of withdrawal symptoms or rebound effects are described following the abrupt cessation of this medicine.


Q: How long does it typically take for a person to start noticing the effects of Nexol?

A: Clinical research cited in official regulatory documents indicates that a measurable effect may be observed within 30 minutes in certain study populations. It is important to remember that individual response and onset of effect may vary.


Q: Is Nexol intended for short-term or long-term use?

A: Regulatory labels describe a short course of use for acute conditions, typically lasting no more than four to five days. However, official safety studies have also examined the drug’s profile over extended periods, up to one year, in certain patient groups.


Q: Can Nexol tablets be crushed or split in half?

A: The official regulatory label specifies that extended-release capsules are intended to be swallowed whole to maintain their sustained-release profile. For immediate-release tablets, the official instructions do not typically permit crushing or splitting.


Q: Is Nexol safe for older patients (seniors) to use?

A: Official documents establish use for the general adult population and do not categorize the elderly as a restricted group. However, caution and dose adjustments are mandated for patients with severe organ impairment, which may be more common in older adults.


Q: What is the meaning of the medical term used to describe Nexol's mechanism in the body?

A: The medicine is officially classified as a mucolytic agent, meaning its primary action is to help break down thick mucus. The term 'proton pump' refers to the H^+/K^+-ATPase enzyme, which is the mechanism described for modulating acid secretion in the stomach.


Q: Does taking Nexol cause any changes in sleep patterns?

A: Changes in sleep patterns, such as sleep disturbance, are not listed as a common adverse reaction in the official safety profile. However, this outcome was monitored as a patient-reported measure in specific clinical trials examining chronic pain conditions.

How should Nexol be stored and disposed of?

Storage and Disposal Requirements for Nexol

Nexol (Ambroxol hydrochloride) requires specific storage and handling to maintain its quality and efficacy. The medication must be kept out of the sight and reach of children at all times.


Storage Conditions

Temperature: Store the product at a temperature generally not exceeding 25 C to 30 C and protect from light.

Handling: Keep the medicine in its original package. Liquid forms should be closed well after each use. Stability for oral solutions may be limited (e.g., 1 month) after first opening.

Disposal

Unused or expired Nexol must not be thrown away via wastewater or household waste. Disposal should be carried out in accordance with local requirements for pharmaceutical waste, often by returning the medicine to a pharmacist or participating in a community drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nexol found in:

A-Z Index: